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Purpose: The aim of the present study was to establish the inherent stability of cefazolin through stress 
studies under a variety of ICH recommended test conditions and, also to develop a stability indicating 
assay. 
Methods: A stability-indicating HPLC assay method was developed and validated for cefazolin using an 
isocratic RP-HPLC method which employed an SS Wakosil II- C18 column (250 mm × 4.6 mm i.d., 5 µm) 
with a mobile phase consisting of phosphate buffer (pH 6.8) and methanol (5:2 v/v), and UV detection at 
254 nm at a flow rate of 1 ml/min. The stress testing of cefazolin was carried out under acidic, alkaline, 
neutral, oxidation and thermal conditions.  
Results: The drug peak was well resolved from the peaks of the degradation products. The proposed 
method was validated for sensitivity, selectivity, linearity, accuracy, precision and solution stability. From 
the degradation studies it was found that the drug was thermally stable but unstable in acidic, alkaline, 
neutral and oxidative conditions. The response of drug was linear in the concentration Range of 1 - 50 
µg/ml with the number of theoretical plates, and tailing factor being 1341 and 1, respectively. Limit of 
detection and limit of quantification were 0.1 and 0.2, µg/ml respectively while recovery ranged from 95 - 
100%. Method precision and precision of the system were within the limits of acceptance criteria.  
Conclusion: This study presents a simple and validated stability-indicating HPLC method for the 
estimation of cefazolin in the presence of degradation products. The developed method is specific, 
accurate, precise and robust. All the degradation products formed during forced degradation studies 
were well separated from the analyte peak. 
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INTRODUCTION 
 
Stability is defined as the capacity of a drug 
substance or drug product to remain within 
established specifications to maintain its 
identity, strength, quality, and purity 
throughout the re-test or expiration dating 
periods [1]. Stability testing of an active 
substance or finished product provides 
evidence on how the quality of a drug 
substance or drug product varies with time. 
It is influenced by a variety of environmental 
factors such as temperature, humidity and 
light. Knowledge from stability studies 
enables understanding of the long-term 
effects of the environment on drugs. Stability 
testing provides information about 
degradation mechanisms, potential 
degradation products, possible degradation 
pathways of the drug as well as interaction 
between the drug and excipients in the drug 
product. The results are applied in 
developing manufacturing processes  and 
selecting proper packaging, storage 
conditions, product's shelf life and expiration 
dates [2-4]. Because the distribution 
environment is highly variable, products 
must be distributed in a manner that ensures 
product quality will not be adversely 
affected. The effect of possible temperature 
and humidity fluctuations, outside of labelled 
storage conditions, during transportation of 
drug products can be evaluated on the basis 
of the stability analysis of the drug [4,5]. 
 
Determination of cefazolin by various 
methods has been described but the stability 
of cefazolin has only been evaluated with 
electrophoresis [6], calorimetry [7] and  
gamma radiations [8]. A number of high 
performance liquid chromatographic (HPLC) 
methods have been developed for the 
cephalosporins in plasma [9-13] but only a 
few stability-indicating HPLC methods for 
drug analysis has been reported [14,15]. 
The aim of the present study was to 
establish the inherent stability of cefazolin 
through stress studies under a variety of 
ICH-recommended tests conditions [2] and 
to develop a stability-indicating assay for the 
drug [16].  
 
Cefazolin sodium [17] is (6R, 7R)-3-(((5-
Methyl-1, 3,4-thiadiazol-2-yl) thio -methyl)-8-
oxo-7-2-(1H-tetrazol-1-yl) acetamido)-5-thia-
1-azabicyclo (4.2.0) oct-2-ene-2-carboxylate 
with molecular formula C14H14N8O4S3. It is a 
first generation cephalosporin and it inhibits 
cell wall biosynthesis. Cephalosporins are 
bactericidal and have the same mode of 
action as other beta-lactam antibiotics (such 
as the penicillins). Modified cephalosporins 
have a much wider activity than the 
penicillins, and also show less toxicity and 






Pure cefazolin was received as a gift from 
Karnataka Antibiotics Pharmaceuticals Ltd, 
Bangalore, India. Cefazolin injection (Azolin 
Injection, 500mg, Biochem-Pharmaceutical 
Industries, Mumbai, India) was purchased 
from local drug market. HPLC grade 
methanol was purchased from Qualigens 
Fine Chemicals, Mumbai, India. Millipore 
water was obtained with Millipak 0.22 µm 
filter. Buffer materials and all other 
chemicals were of analytical-reagent grade.  
 
 Instrumentation and chromatographic 
conditions 
 
The HPLC system consisted of model 10AT 
Shimadzu- SPD10A detector an SS Wakosil 
II- C18 column (250 mm × 4.6 mm i.d., 5 µm). 
Separation was carried out by isocratic 
elution with a mixture of phosphate buffer (pH 
6.8) and methanol in the ratio of 5:2 (v/v) at a 
flow rate of 1 ml/min. The detector was 
monitored at 254 nm and the injection volume 
was 100 µl.  
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Preparation of standard and sample 
solutions 
 
Standard preparation: A standard stock 
solution of 1 mg/ml of cefazolin in the mobile 
phase was prepared in a 10 ml volumetric 
flask. Working standard solutions were 
prepared by diluting the stock solution with 
the mobile phase to obtain cefazolin 
concentrations ranging from 0.1 – 100 µg/ml.  
 
Sample preparation: Cefazolin sodium 
injection of 500 mg was dissolved in 2 ml 
water for injection and from this solution, a 
working sample solution of 2µg/ml was 
prepared with the mobile phase in a 10 ml 
volumetric flask and filtered through a 0.22 




Standard cefazolin with a concentration of 
1 mg/ml was used in all the degradation 
studies. Standard cefazolin solutions were 
subjected to stress conditions in 0.1N HCl 
and 0.1N NaOH at of temperature of 80 °C at 
time intervals. After completion of the 
degradation processes, the solutions were 
neutralized and diluted with mobile phase. 
For neutral studies, standard cefazolin of 
1 mg/ml was dissolved in water and 
subjected to stress conditions at a 
temperature of 80 °C at time intervals. For 
the oxidative studies, the standard cefazolin 
solution was subjected to stress conditions in 
3 and 30% hydrogen peroxide at room 
temperature for 30 min. After the solutions 
had been subjected to the various stress 
conditions, 0.1 ml of the degraded solutions 
were withdrawn at the various intervals and 
subjected and analysed after suitable dilution 
to 10 µg/ml with mobile phase. The 
chromatographic analysis of the degraded 
solutions (100 µl each) were carried out 




Analytical method validation was carried out 
as per ICH method validation guidelines [16]. 
The validation parameters addressed were 
specificity, precision (inter-day and intra-day), 
linearity, accuracy, limit of detection, limit of 
quantitation, robustness and stability of 
cefazolin in mobile phase. A standard plot 
was constructed for cefazolin in the range of 
0.1 – 50 µg/ml. Accuracy was determined by 
fortifying the mixture of pre-analysed 
standard of three known concentrations of 




Development and optimization of the 
stability-indicating HPLC method 
 
An isocratic method was found suitable to 
optimise the separation of major degradation 
products formed under various stress 
conditions. The best resolution was 
achieved with an initial run of a mixture of 
phosphate buffer (pH 6.8) and methanol in 
the ratio of 5:2 (v/v) at a flow rate of 1 
ml/min; the retention time was observed to 




HPLC data on samples (powder and solution 
combination) obtained on stress testing 
(alkaline, acidic, neutral, thermal and 





The standard drug cefazolin at 80 
0
C in 
0.1 M HCl was degraded in 5 min. Within 10 
min 87.5 % drug was degraded. The 
chromatogram showed major degradation 
products at retention times (RT) of 2.96 min 





The drug was highly degraded in 0.1 M 
NaOH at 80 
0
C, being degraded within 10 
min. Three major degradation peaks at RT of 
2.00, 2.26, and 2.96 min were observed while  
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Table 1:  Degradation data for cefazolin 
 
    *Mean of three measurements 
 




















2 2 4 534115 3.9 1.9 95 
4 2 6 761349 5.8 3.8 95 





The degradation of standard cefazolin 
solution was highly labile in neutral medium 
(water) at room temperature (27 ± 2 
0
C) with 
33.3 % of the drug decomposed in 60 min. 
The major degradation product appeared at 
RT of 2.50 min and the standard peak at 




The degradation of cefazolin in 3 % 
hydrogen peroxide (oxidative conditions) at 
different time interval of 20 min was 29.9 %, 
giving rise to one degraded peak at RT of 2 
min with the hydrogen peroxide and 
standard peaks occurring at RT of 2.98 and 
5.90 min, respectively. In 30 % hydrogen 
peroxide, 95.6 % drug was degraded in 10 
min with the degradation peak occurring at 
RT of 1.97 min. Hydrogen peroxide and 
standard peaks occurred at 3.01 and 5.95 





Under thermal degradation conditions, 
standard cefazolin solution was stable for 24 
h. exposition at 50 °C. After 48 h of thermal 
stress, 29.89 % of cefazolin was degraded, 
while 70.10 % (did not any degraded peaks) 
was recovered. 
                      




The retention time of cefazolin was 5.67 min. 
Efficiency and tailing factor at 5 % of the 
height of the main peak were determined, 









Active drug present 
after degradation (%) 
Standard drug - 1683293 - - 
Acidic 10  108335 87.53 12.46 
Alkaline 10  412316 61.88 38.10 
Neutral 30  1088441 17.01 82.98 
Neutral 60  746143 33.29 66.11 
Oxidative (3% H2O2) 20  1712823 70.33 29.88 
Oxidative (30 %H2O2) 
30 min 393803 95.6 5.36 
Thermal 36 hr 1180032 29.89 70.10 
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Linearity 
 
Ten-point calibration curves were obtained in 
a concentration range of 1 to 50 µg/ml for 
cefazolin based on three independent 
determinations performed at each 
concentration. The response for the drug was 
linear and the calibration equation was y = 
291171x - 26955 with R
2
 = 0.9989.  
 
Limit of detection (LOD) and limit of 
quantitation (LOQ) for cefazolin  
 
The limit of detection and limit of quantitation 





Recovery ranged from 95 – 100 %. The 
recovery study data are given in Table 2. 
 
Precision 
Method precision and precision of the system 
were within the limits of acceptance criteria. 
Assessment of the system precision showed 
that the relative standard deviation was 
0.8033 and 0.5856 % for 4 and 2 mcg, 
respectively. The data for inter- and intra-day 




The ruggedness of the developed method 
was established by determining cefazolin in 
the same chromatographic system and the 
same column by two analysts on different 
days. The assay result indicated that the 
method had a high precision. Additionally, 
good separation, effective separation of the 
drug from its degraded product was always 
achieved which suggests that the method 




The stability of cefazolin solution was 
established by keeping the solution at room 
temperature for 24 h. The result showed no 
significant change in concentration, thus 
confirming the stability of the drug in the 




In this study, the inherent stability of cefazolin 
was established based on tests utilising ICH 
recommended stress conditions. The drug 
degraded extensively in alkaline, acidic, 
neutral and oxidative conditions. Mild 
degradation was seen in thermal conditions 
without any degraded products. Drug peak 
was well resolved from the peak of its 
degradation product as well as those of the 
excipients in cefazolin sodium injection 
formulation. The developed method was 
simple, accurate, precise, specific, selective 
and rugged and, therefore, it should be 
suitable for the analysis of cefazolin and its 
degraded products of the drug product in the 
industry. 
 








conc. (µg/ml) µg/ml) RSD (%, n = 3)  µg/ml) RSD (%, n = 3) 
1 0.9 1.8153 0.9 0.6509 
2 2.0 1.9191 2.0 0.9329 
4 3.9 1.7236 3.9 1.3516 
6 5.7 0.5500 5.6 1.2570 
8 7.7 1.6507 8.2 1.9843 
10 10.2 0.6146 10.1 1.0525 
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CONCLUSION 
 
This study presents a simple and validated 
stability-indicating HPLC method for the 
estimation of cefazolin in the presence of its 
degradation products. The developed method 
is specific, accurate, precise and robust. All 
the peaks of the degradation products formed 
during forced decomposition studies were 
well separated from the analyte peak. This 
demonstrates that the developed method was 
specific and stability-indicating. The method 
was successfully applied to the analysis of a 
commercial cefazolin injection formulation, as 
no interference due to excipients or other 
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